Market Cap 174.04M
Revenue (ttm) 10,000.00
Net Income (ttm) -42.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18,756.25%
Debt to Equity Ratio 0.14
Volume 214,575
Avg Vol 360,054
Day's Range N/A - N/A
Shares Out 22.93M
Stochastic %K 28%
Beta 1.86
Analysts Strong Sell
Price Target $22.29

Latest News on INMB

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:15 PM EDT - 6 days ago

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript


INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 8:09 PM EDT - 5 months ago

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript


INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 13, 2024, 8:30 AM EDT - 7 months ago

INmune Bio Announces $13.0 Million Registered Direct Offering


INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 11:50 PM EDT - 8 months ago

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript


INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

Jul 8, 2024, 6:12 AM EDT - 9 months ago

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro


INmune Bio Inc. to Join Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 11 months ago

INmune Bio Inc. to Join Russell 3000® Index


INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:58 PM EDT - 11 months ago

INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript


INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

Apr 22, 2024, 4:27 AM EDT - 1 year ago

INmune Bio: An Opportunity In The Freefall (Rating Upgrade)


INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:18 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript